Loading…
Sutro Biopharma, Inc. is projected to rise to $31.55 by 2027, a +31% move from its current price of $24.17. STRO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $23.28 | $24.20 | $25.15 | +0.11% |
| Aug 4 | $22.93 | $24.22 | $25.59 | +0.22% |
| Aug 5 | $22.68 | $24.25 | $25.93 | +0.33% |
| Aug 6 | $22.47 | $24.28 | $26.23 | +0.44% |
| Aug 7 | $22.29 | $24.30 | $26.50 | +0.55% |
| Aug 8 | $22.13 | $24.33 | $26.75 | +0.66% |
| Aug 9 | $21.99 | $24.36 | $26.98 | +0.78% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.99 | $24.36 | $26.98 | +0.78% |
| Week 2 | $21.24 | $24.55 | $28.37 | +1.56% |
| Week 3 | $20.72 | $24.74 | $29.53 | +2.35% |
| Week 4 | $20.31 | $24.93 | $30.59 | +3.14% |
| Week 5 | $19.98 | $25.12 | $31.58 | +3.94% |
| Week 6 | $19.70 | $25.32 | $32.53 | +4.75% |
| Week 7 | $19.46 | $25.51 | $33.45 | +5.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sutro Biopharma, Inc. is an oncology-focused biopharmaceutical company. It develops site-specific and novel-format antibody drug conjugates (ADCs) that enable its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+.
Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that are in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and in infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc.
has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma, Inc. (STRO) is a healthcare company focused on oncology with a portfolio of ADCs and vaccine candidates. The stock currently trades with a market cap of $393.22M and a market rank of 3179.
The price outlook is shown by a multi-year forecast, indicating a potential path of upside in several future years, alongside notable near-term variability.
A major floor 34.0% below — a decisive break under it would weaken the trend.
The nearest floor, 6.5% below — buyers have tended to step in here.
The nearest ceiling, 38.0% above — a clean break opens room to run.
A major ceiling 69.3% above — clearing it would confirm fresh momentum.
Key STRO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of STRO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.01 | Buy | $24.04 | Buy |
| MA 10 | $23.55 | Buy | $24.26 | Sell |
| MA 20 | $25.85 | Sell | $25.41 | Sell |
| MA 50 | $27.64 | Sell | $27.29 | Sell |
| MA 100 | $28.85 | Sell | $26.47 | Sell |
| MA 200 | $20.71 | Buy | $23.11 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.09 | Neutral |
| Stoch RSI (14) | 82.90 | Sell |
| CCI (20) | -40.91 | Neutral |
| Williams %R (14) | -54.07 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -7.04 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 45.93 | Neutral |
| TRIX (15) | -0.81 | Sell |
| Awesome (5,34) | -3.65 | Sell |
| Ultimate (7,14,28) | 47.81 | Neutral |
| Momentum (10) | 0.60 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 24.30 | Sell |
| ADX (14) | 20.00 | Sell |
| ATR (14) | 0.94 | Info |
The 30-day technical picture is neutral, with RSI(14) at 30. The stock trades above the 200-day SMA of $19.89 but below the 50-day SMA of $30.83, suggesting a mixed momentum picture. The current price of $23.73 sits at the stated support level of $23.73 and below the resistance at $33.35, indicating potential for movement if price breaks above resistance or tests support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.63 | $24.17 | $35.31 | 0% | Neutral | |
| $24.21 | $31.55 | $43.99 | +31% | Bullish | |
| $24.33 | $33.06 | $48.48 | +37% | Bullish | |
| $22.39 | $31.51 | $48.04 | +30% | Bullish | |
| $25.65 | $37.25 | $58.63 | +54% | Bullish | |
| $28.12 | $42.01 | $68.01 | +74% | Bullish | |
| $31.78 | $48.78 | $80.95 | +102% | Bullish | |
| $38.64 | $60.84 | $103.24 | +152% | Bullish | |
| $37.30 | $60.19 | $104.23 | +149% | Bullish | |
| $34.87 | $57.61 | $101.67 | +138% | Bullish | |
| $49.41 | $91.07 | $173.81 | +277% | Bullish | |
| $85.10 | $189.11 | $403.57 | +682% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $10.63 | $24.17 | $28.93 | +0.00% |
| September 2026 | $20.91 | $25.04 | $31.05 | +3.61% |
| October 2026 | $22.11 | $26.73 | $33.63 | +6.74% |
| November 2026 | $22.11 | $26.95 | $34.32 | +0.83% |
| December 2026 | $22.34 | $27.43 | $35.31 | +1.77% |
Click any year to see its month-by-month STRO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect STRO to range from $10.63 to $35.31 through 2026. The $24.17 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The STRO price prediction for 2027 points to an average of $31.55 (low $24.21, high $43.99) — a potential gain of +31% on today's $24.17. Momentum favours further upside here.
In 2028, STRO is projected to trade between $24.33 and $48.48, averaging $33.06 — a potential gain of +37% from today's $24.17. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Sutro Biopharma, Inc.'s 2029 outlook centres on $31.51, within a $22.39 to $48.04 range. That is -5% versus the projected 2028 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2030, STRO could reach as high as $58.63, with a base case around $37.25 and support toward $25.65 — roughly +54% from $24.17. Buyers look set to stay in control over this stretch.
Expect STRO to range from $28.12 to $68.01 through 2031. The $42.01 average target implies a +74% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The STRO price prediction for 2032 points to an average of $48.78 (low $31.78, high $80.95) — a potential gain of +102% on today's $24.17. Buyers look set to stay in control over this stretch.
In 2033, STRO is projected to trade between $38.64 and $103.24, averaging $60.84 — a potential gain of +152% from today's $24.17. That is up +25% on the projected 2032 average. Momentum favours further upside here.
Sutro Biopharma, Inc.'s 2034 outlook centres on $60.19, within a $37.30 to $104.23 range. That is -1% versus the projected 2033 average. That marks a +149% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, STRO could reach as high as $101.67, with a base case around $57.61 and support toward $34.87 — roughly +138% from $24.17. Momentum favours further upside here.
Expect STRO to range from $49.41 to $173.81 through 2040. The $91.07 average target implies a +277% move from current prices. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The STRO price prediction for 2050 points to an average of $189.11 (low $85.10, high $403.57) — a potential gain of +682% on today's $24.17. Momentum favours further upside here.
Investing $1,000 in STRO today (≈ 41.373604 STRO) could be worth
$7,824.19
+$6,824.19 (+682%) by 2050 · US Dollar
Based on the average projected STRO price of $189.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in STROwould be worth at today's price.
$1,000 invested in STRO on Jul 31, 2025 (≈ 123.456784 STRO) would be worth
$2,983.95
+$1,983.95 (+198.4%) today · 2.98× · US Dollar
Based on a STRO entry price of $8.1 vs. today's $24.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $22.88 | $1,056.38 | +5.6% |
| 1 month ago | $30.24 | $799.27 | -20.1% |
| 3 months ago | $35.59 | $679.12 | -32.1% |
| 6 months ago | $15.1 | $1,600.66 | +60.1% |
| 1 year ago | $8.1 | $2,983.95 | +198.4% |
| All time (5.0y) ago | $179 | $135.03 | -86.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our STRO forecast.
Our base-case forecast reaches $48.00 around 2032.
Implied market cap at $48.00: $795.38M
The multi-year forecast shows a bullish trajectory from 2027 onward, with the average price rising from $31.08 in 2027 to $153.28 in 2050 and the ROI increasing from 31% to 545.9%. Notably, 2030 is forecast at an average of $33.43 with a 40.9% ROI, 2032 at $43.76 with an 84.4% ROI, and 2033 at $55.14 with a 132.4% ROI. The forecast also shows substantial upside by 2040 ($73.08 average, 208% ROI) and by 2050 ($153.28 average, 545.9% ROI).
While these figures suggest strong potential upside, they are estimates and not guarantees. The 2026 forecast ranges from a minimum of $10.63 to a maximum of $37.49, with an average of $23.73 and neutral sentiment in that year.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $33.43 with a minimum of $21.64 and a maximum of $55.79, with a 40.9% ROI and bullish sentiment.
The forecast shows bullish sentiment from 2027 onward, with averages from $31.08 in 2027 to $153.28 in 2050 and ROIs up to 545.9% in 2050.
Yes. The 2033 forecast lists a maximum of $100.24, with 2033 min $32.10 and max $100.24.
The 30-day range is $17.38 to $32.41.
Sutro Biopharma, Inc. Community Discussion
0Share your Sutro Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.